- Shares of GSK, Sanofi and Haleon all sold off sharply this week amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac.
- This has been a known issue bumbling in the background for years but investor concern exploded this week in the lead-up to the first scheduled legal proceeding.
- For many investors and analysts, this ordeal brings back memories of the Bayer Roundup saga.
In this article
